In this issue of JAMA Psychiatry, DeRubeis et al1 present the second phase of an elegantly designed study that has yielded results that will inform patient care and future research. A paucity of studies is available to inform the long-term treatment of persistent major depressive disorder (MDD), either chronic or recurrent.2 Most studies have focused on short-term treatment with single interventions, and many longer-term studies have not been controlled.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Freeman MP. Relapse Prevention After Recovery in Patients With Persistent Major Depressive Disorder—An Active Pursuit. JAMA Psychiatry. 2020;77(3):231–232. doi:10.1001/jamapsychiatry.2019.3637
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.